National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Malignant Mesothelioma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 01/09/2009



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Localized Malignant Mesothelioma (Stage I)






Advanced Malignant Mesothelioma (Stages II, III, and IV)






Recurrent Malignant Mesothelioma






Get More Information From NCI







Changes to This Summary (01/09/2009)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Questions about cancer?

1-800-4-CANCER
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to the Nation Finds Continued Declines in Cancer Rates
Changes to This Summary (01/09/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Advanced Malignant Mesothelioma (Stages II, III, and IV)

Added text about a randomized phase III trial that compared cisplatin alone with the combination of raltitrexed and cisplatin in first-line treatment of patients with malignant pleural mesothelioma (cited van Meerbeeck et al. as reference 19 and level of evidence 1iiA).

Recurrent Malignant Mesothelioma

Added Zucali et al. as reference 3. Added text to state that patients with recurrent mesothelioma but without prior chemotherapy are candidates for first-line chemotherapy with cisplatin pemetrexed or cisplatin raltitrexed; patients who receive surgery without chemotherapy and recur are candidates for chemotherapy.

Added text about a study that compared pemetrexed to best supportive care in patients who received one prior regimen of chemotherapy without pemetrexed (cited Jassem et al. as reference 6 and level of evidence 1iiA).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov